The company's compounds, RV-568 and RV-1088, narrow spectrum kinase inhibitors with a profile of anti-inflammatory activities, are progressing into clinical development as potential treatments for moderate to severe asthma, Chronic Obstructive Pulmonary Disease (COPD) and Cystic Fibrosis (CF).
The clinical development of RV-568 and RV-1088 will be led by RespiVert in collaboration with scientists at Centocor Research and Development.
With the acquisition of RespiVert, Centocor is expected to gain a portfolio of inhaled treatments for serious lung diseases. RespiVert will continue to maintain its research and discovery presence in London from the Imperial BioIncubator, which is based at the campus of Imperial College London.
Susan Dillon, Global Therapeutic area head for Immunology at Centocor Research and Development, said: “The RespiVert compounds offer the potential for a new class of medicines for patients with severe lung disease who are insensitive to inhaled corticosteroids.”
Garth Rapeport, CEO of RespiVert, said: “We believe that our focused discovery efforts in pulmonary disease offer a unique opportunity to bring completely new treatment options to patients who suffer from severe, chronic respiratory diseases including Chronic Obstructive Pulmonary Disease, severe asthma and Cystic Fibrosis.”
Will this acquisition benefit Centocor Ortho Biotech?
Have your say and discuss with your peers on the InfoGrok community.
Participate by posting your comments now.